# Arbutus (ABUS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ABUS
## Company Profile
- Ticker: ABUS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Canada
- Tags: Nucleic Acid Drugs, Infectious Disease
## Stock Data
- Close: 4.62 USD
- Market cap: 841510644.5999999 USD
- Last updated: 2026-08-05
## Business Overview
### Hepatitis B Therapeutics Company
Arbutus Biopharma develops combination therapies intended to achieve a functional cure for chronic hepatitis B.
### Imdusiran
Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins, including surface antigen, and is being studied in combination regimens.
### Combination Strategy
The company’s development approach pairs viral antigen suppression with immune-modulating agents to seek durable off-treatment control.
### Genevant Economics
Arbutus also retains economic exposure to lipid nanoparticle intellectual property through Genevant and related licensing and litigation arrangements.
## Why The Stock Is Moving

As of Aug 5, 2026, ABUS closed up 4.52% at $4.62. No new same-company headline was identified in the current news window.

## Future Catalysts

- What matters most for Arbutus from here is imdusiran. That matters because the company is now talking about continued work around imdusiran and the next company-specific development update. That is the piece most likely to shape sentiment in the near term.

## Recent News
- 2026-07-16 11:30 EST — [Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders](https://biopharmsignal.com/news/ABUS/arbutus-initiates-international-patent-infringement-enforcement-actions-against--c6198417) — Source: Arbutus
- 2026-05-13 11:30 EST — [Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ABUS/arbutus-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Arbutus
- 2026-04-15 11:30 EST — [Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B](https://biopharmsignal.com/news/ABUS/arbutus-receives-u-s-fda-fast-track-designation-for-imdusiran-for-the-treatment-of-chronic-hepatitis-b) — Source: Arbutus
- 2026-03-23 11:30 EST — [Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ABUS/arbutus-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-corporate-update) — Source: Arbutus
- 2026-03-03 21:15 EST — [Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna](https://biopharmsignal.com/news/ABUS/genevant-sciences-and-arbutus-biopharma-announce-2-25-billion-global-settlement-with-moderna) — Source: Arbutus